NCT00929643View on ClinicalTrials.gov

Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections

CompletedOBSERVATIONAL
Enrollment

203

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Complicated Intra-Abdominal Infection
Interventions
OTHER

no intervention

success of the initial empiric treatment

Trial Locations (13)

26500

Pfizer Investigational Site, Rio

54636

Pfizer Investigational Site, Thessaloniki

56429

Pfizer Investigational Site, Thessaloniki

70013

Pfizer Investigational Site, Heraklion

115 24

Pfizer Investigational Site, Athens

115 26

Pfizer Investigational Site, Athens

115 27

Pfizer Investigational Site, Cholargós

124 62

Pfizer Investigational Site, Haidari

151 26

Pfizer Investigational Site, Marousi

142 33

Pfizer Investigational Site, N. Ionia

184 54

Pfizer Investigational Site, Peireus

546 35

Pfizer Investigational Site, Thessaloniki

546 42

Pfizer Investigational Site, Thessaloniki

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

collaborator

Pfizer

INDUSTRY

NCT00929643 - Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections | Biotech Hunter | Biotech Hunter